Exclusive Summary

• - Patent long expired and US registration completed, enabling rapid distribution via reliance pathways across multiple markets.
• - Two standard 300 mg/mL strengths cover routine and high-dose inpatient needs, simplifying hospital procurement and tenders.
• - Addresses the non–beta-lactam need in patients with reported penicillin allergy (about 8–10% globally) requiring anaerobic/Gram-positive coverage.
• - Mature generic with broad global supply; typically 40–80% cheaper than originator, delivering clear cost advantage in price-sensitive markets.
• - US compliance and registration enhance buyer confidence and facilitate entry into reliance/regulatory-reference markets in LATAM/MENA/SSA.